Regulus adds Biogen to partner roster
This article was originally published in Scrip
Regulus Therapeutics and Biogen Idec have entered into a collaboration to identify microRNAs as biomarkers for multiple sclerosis. Biogen will invest in Regulus and pay the San Diego-based company undisclosed upfront and milestone fees.
You may also be interested in...
Development of gosuranemab in tauopathies will end after a Phase II progressive supranuclear palsy trial failure, but a Phase II Alzheimer’s study of the drug licensed from BMS is ongoing.
Public Company Edition: The last biopharma initial public offering in the US was on 11 November, but follow-on and other offerings are generating hundreds of millions of dollars. Among RNA drug developers, Ionis issued more than $500m in new debt, while Arrowhead raised $266.8m.
Private Company Edition: Omega raised $438m for its sixth life science fund, while Perceptive and the accelerator Xontogeny partnered on a new $210m venture capital fund. In VC deals, Zentalis and Black Diamond raised $85m each.